HBIO - Harvard Bioscience, Inc.
NASDAQ
->
Healthcare
->
Medical Instruments & Supplies
Holliston,
United States
Type: Equity
HBIO price evolution
HBIO
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4.25 | $4.28 | $5.34 | $4.32 |
| Short term investments | ||||
| Net receivables | $15.31 | $16.1 | $14.98 | $16.9 |
| Inventory | $24.14 | $24.72 | $25.82 | $26.09 |
| Total current assets | $48.15 | $49.04 | $50.49 | $52.62 |
| Long term investments | ||||
| Property, plant & equipment | $8.85 | $8.75 | $8.42 | $8.74 |
| Goodwill & intangible assets | $71.38 | $73.1 | $73.32 | $75.13 |
| Total noncurrent assets | $85.01 | $88.33 | $89.25 | $90.28 |
| Total investments | ||||
| Total assets | $133.16 | $137.37 | $139.74 | $142.9 |
| Current liabilities | ||||
| Accounts payable | $6.04 | $5.55 | $6.27 | $4.72 |
| Deferred revenue | $4.39 | $4.51 | $4 | $3.83 |
| Short long term debt | $4.92 | $7.28 | $5.59 | $5.34 |
| Total current liabilities | $25.68 | $26.54 | $24.2 | $22.94 |
| Long term debt | $36.45 | $35.5 | $39.69 | $42.86 |
| Total noncurrent liabilities | $38.67 | $37.75 | $41.24 | $44.57 |
| Total debt | $41.36 | $42.77 | $45.29 | $48.2 |
| Total liabilities | $64.35 | $64.29 | $65.45 | $67.51 |
| Shareholders' equity | ||||
| Retained earnings | -$150.3 | -$145.6 | -$143.79 | -$142.55 |
| Other shareholder equity | -$14.77 | -$14.19 | -$15.28 | -$14.05 |
| Total shareholder equity | $68.81 | $73.07 | $74.29 | $75.39 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4.28 | $4.51 | $7.82 | $8.32 |
| Short term investments | ||||
| Net receivables | $16.1 | $20.18 | $21.83 | $17.77 |
| Inventory | $24.72 | $26.44 | $27.59 | $22.26 |
| Total current assets | $49.04 | $51.12 | $61.58 | $51.7 |
| Long term investments | ||||
| Property, plant & equipment | $8.75 | $9.18 | $10.31 | $11.72 |
| Goodwill & intangible assets | $73.1 | $77.27 | $85.07 | $91.74 |
| Total noncurrent assets | $88.33 | $94.24 | $100.76 | $104.55 |
| Total investments | ||||
| Total assets | $137.37 | $145.36 | $162.34 | $156.25 |
| Current liabilities | ||||
| Accounts payable | $5.55 | $6.45 | $4.91 | $5.97 |
| Deferred revenue | $4.51 | $3.37 | $4.27 | $3.77 |
| Short long term debt | $7.28 | $5.95 | $5.38 | $3.83 |
| Total current liabilities | $26.54 | $23.25 | $25.32 | $21.05 |
| Long term debt | $35.5 | $43.01 | $51.58 | $53.77 |
| Total noncurrent liabilities | $37.75 | $49.89 | $53.63 | $58.52 |
| Total debt | $42.77 | $54.24 | $56.96 | $57.6 |
| Total liabilities | $64.29 | $73.14 | $78.94 | $79.57 |
| Shareholders' equity | ||||
| Retained earnings | -$145.6 | -$142.19 | -$132.67 | -$132.39 |
| Other shareholder equity | -$14.19 | -$15.05 | -$10.03 | -$13.07 |
| Total shareholder equity | $73.07 | $72.22 | $83.4 | $76.68 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $24.51 | $28.15 | $25.36 | $28.76 |
| Cost of revenue | $9.74 | $11.83 | $10.64 | $12.09 |
| Gross Profit | $14.77 | $16.32 | $14.73 | $16.67 |
| Operating activities | ||||
| Research & development | $2.88 | $3.15 | $2.76 | $2.96 |
| Selling, general & administrative | $11.87 | $11.51 | $11.54 | $11.53 |
| Total operating expenses | $17.05 | $16.04 | $15.66 | $15.88 |
| Operating income | -$2.28 | $0.28 | -$0.93 | $0.8 |
| Income from continuing operations | ||||
| EBIT | -$3.73 | -$0.31 | $0.32 | -$1.16 |
| Income tax expense | $0.21 | $0.71 | $0.68 | -$1.12 |
| Interest expense | $0.75 | $0.79 | $0.88 | $0.94 |
| Net income | ||||
| Net income | -$4.69 | -$1.82 | -$1.24 | -$0.98 |
| Income (for common shares) | -$4.69 | -$1.82 | -$1.24 | -$0.98 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $112.25 | $113.33 | $118.9 | $102.1 |
| Cost of revenue | $46.18 | $52.52 | $51.25 | $44.06 |
| Gross Profit | $66.07 | $60.82 | $67.65 | $58.04 |
| Operating activities | ||||
| Research & development | $11.76 | $12.33 | $10.8 | $8.69 |
| Selling, general & administrative | $46.89 | $49.53 | $48.95 | $43.42 |
| Total operating expenses | $64.18 | $67.75 | $65.59 | $57.82 |
| Operating income | $1.89 | -$6.93 | $2.07 | $0.22 |
| Income from continuing operations | ||||
| EBIT | $1.03 | -$6.63 | $1.4 | -$2.46 |
| Income tax expense | $0.86 | $0.34 | $0.15 | $0.52 |
| Interest expense | $3.59 | $2.55 | $1.54 | $4.83 |
| Net income | ||||
| Net income | -$3.42 | -$9.52 | -$0.29 | -$7.81 |
| Income (for common shares) | -$3.42 | -$9.52 | -$0.29 | -$7.81 |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Net income | -$4.69 | -$1.82 | -$1.24 | -$0.98 |
| Operating activities | ||||
| Depreciation | $1.78 | $1.78 | $1.78 | $1.72 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.05 | $1.38 | $1.36 | $1.1 |
| Total cash flows from operations | $1.4 | $4.3 | $4.36 | $3.55 |
| Investing activities | ||||
| Capital expenditures | -$0.72 | -$1.35 | -$0.22 | -$0.52 |
| Investments | $0.49 | |||
| Total cash flows from investing | -$0.23 | -$1.06 | -$0.4 | -$0.63 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.01 | $0.21 | $0.62 | |
| Net borrowings | -$1.02 | -$2.25 | -$2.75 | -$2.7 |
| Total cash flows from financing | -$1.05 | -$4.12 | -$2.75 | -$2.38 |
| Effect of exchange rate | -$0.15 | -$0.18 | -$0.19 | -$0.02 |
| Change in cash and equivalents | -$0.03 | -$1.06 | $1.02 | $0.54 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$3.42 | -$9.52 | -$0.29 | -$7.81 |
| Operating activities | ||||
| Depreciation | $7 | $7.58 | $7.62 | $7.63 |
| Business acquisitions & disposals | $0.51 | |||
| Stock-based compensation | $5 | $4.41 | $4.17 | $3.65 |
| Total cash flows from operations | $14.03 | $1.15 | $1.26 | $9.33 |
| Investing activities | ||||
| Capital expenditures | -$2.31 | -$1.59 | -$1.34 | -$1.15 |
| Investments | ||||
| Total cash flows from investing | -$1.8 | -$1.59 | -$1.34 | -$1.4 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.93 | $0.58 | $3.31 | |
| Net borrowings | -$10.54 | -$1.79 | -$0.05 | -$6.89 |
| Total cash flows from financing | -$12.13 | -$2.84 | -$0.25 | -$7.97 |
| Effect of exchange rate | -$0.32 | -$0.04 | -$0.16 | $0.02 |
| Change in cash and equivalents | -$0.23 | -$3.31 | -$0.5 | -$0.02 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $106.79M |
|---|---|
| EBITDA | $2.18M |
| EBIT | -$4.88M |
| Net Income | -$8.73M |
| Revenue Q/Q | -18.23% |
| Revenue Y/Y | -6.76% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -6.31% |
| ROE | -11.98% |
| Debt/Equity | 0.88 |
|---|---|
| Net debt/EBITDA | 27.58 |
| Current ratio | 1.88 |
| Quick ratio | 0.94 |